Norway· NO-ID_8B35D014-E593-4469-A953-F6E185499E42
Trelegy Ellipta
A vilanterol, umeclidinium bromid und fluticason furoat product containing umeclidinium bromide + fluticasone furoate + vilanterol, registered in Norway by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 11 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Vilanterol, umeclidinium bromid und fluticason furoat is registered in 11 of 19 countries.
Countries holding a registration under ATC R03AL08 (vilanterol, umeclidinium bromid und fluticason furoat), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 7 of them publish a price we can compare per daily dose
Vilanterol, umeclidinium bromid und fluticason furoat · ATC R03AL08
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
FEST (Norway)- Active substance
- Umeclidinium Bromide + Fluticasone Furoate + Vilanterol
- Manufacturer
- GlaxoSmithKline Trading Services Limited
- Country
- Norway (NO)
- ATC code
- R03AL08
- ATC class
- Vilanterol, Umeclidinium bromid und Fluticason furoat
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 5
2 priced- gtin5054626000758
- no_merkevare_idID_8B35D014-E593-4469-A953-F6E185499E42
- no_varenummer1541471 x 30NOK 744.8
- no_varenummer4432283 x 30NOK 2155.6
- gtin5054626000741
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Vilanterol, umeclidinium bromid und fluticason furoat in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandElebrato ElliptaGlaxoSmithKline Trading Services Limited
- United KingdomTrelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhalerGlaxoSmithKline UK Ltd
- SpainELEBRATO ELLIPTA 92 MICROGRAMOS/55 MICROGRAMOS/22 MICROGRAMOS POLVO PARA INHALACION (UNIDOSIS)Glaxosmithkline Trading Services Limited
- SwedenElebrato Ellipta 92 mikrogram/55 mikrogram/22 mikrogram Inhalationspulver, avdelad dosGlaxoSmithKline Trading Services Ltd
- SwitzerlandTrelegy Ellipta, Einzeldosiertes Pulver zur InhalationGlaxoSmithKline AG
- CanadaTRELEGY ELLIPTAGLAXOSMITHKLINE INC
- PolandElebrato ElliptaGlaxoSmithKline Trading Services Limited
- IrelandTrelegy Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder, pre-dispensedGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Elebrato Ellipta, Trelegy Ellipta
- Liechtenstein · Elebrato Ellipta, Trelegy Ellipta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/079f8036-b52a-4a8f-bae8-060015fb6918 GET /v1/drugs/079f8036-b52a-4a8f-bae8-060015fb6918?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Inhalasjonspulver, dosedispensert",
"source": "fest",
"status": "A",
"atc_name": "Vilanterol, umeklidiniumbromid og flutikasonfuroat",
"merkevare_id": "ID_8B35D014-E593-4469-A953-F6E185499E42",
"name_form_strength": "Trelegy Ellipta inh pulv, disp 92 mikrog/55 mikrog/22 mikrog",
"prescription_group": "C"
}See everything about vilanterol, umeclidinium bromid und fluticason furoat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.